News

DaVita reiterates $2.01B–$2.16B adjusted operating income guidance for 2025 as cost controls offset volume headwinds

Q2 2025 Management View Javier J. Rodriguez, CEO, stated that "we are pleased to report another solid quarter where our focus on providing exceptional care for our patients and fostering a positive ...

Amgen outlines $35B–$36B 2025 revenue target as volume growth offsets pricing pressure

Q2 2025 Management View CEO Robert A. Bradway highlighted strong quarterly performance, stating that "revenues grew by 9% year-over-year and volume increased at an impressive 13%, 15 of our products ...